Floatz logo

Omalizumab

Allergic Bronchopulmonary Aspergillosis

Novartis Pharmaceuticalsmonoclonal_antibodyPhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Allergic Bronchopulmonary Aspergillosis cohort.

Asset / SponsorPhaseRating
Itraconazole
Novartis Pharmaceuticals
Phase 4BB
AMPHOTERICIN
Poitiers University Hospital
Phase 2B

Same molecule, other indications

Omalizumab is also rated in:

allergic asthmaDormant
BBB
Indicative ·
76 / 100
View asset →
asthmaDormant
BB
Indicative ·
68 / 100
View asset →
chronic rhinosinusitisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →